A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared for phase 3 trials in asthma – even though it missed the mark in a midstage ...

Positive mid-stage results with Apogee Therapeutics' IL-13 inhibitor APG777 in atopic dermatitis have driven the company's shares up around 20%, as it prepares for a phase 3 programme. The 16-week ...

Another development came in Jon Gruden's appeal against the NFL, as the Nevada Supreme Court unanimously rejected an NFL petition that was seeking a rehearing of an August decision that said Gruden ...

When it comes to keeping your teeth gleaming, there’s a seemingly endless array of options to choose from. The two key players in oral hygiene, Oral-B and Philips, alone offer dozens of different ...